MUMBAI, Aug. 26 (Xinhua) -- India's Wockhardt has partnered with China's Jiangxi Jemincare Group Company to develop and commercialize novel broad-spectrum antibiotic Nafithromycin, the Indian company said in its filing with the Bombay Stock Exchange on Thursday.
Wockhardt has completed global clinical Phase I and II studies with Nafithromycin, which belongs to the lactone/ketolide class for respiratory tract infections.
The antibiotic is active against entire range of bacterial pathogens associated with community-acquired bacterial pneumonia including macrolide resistance strains which is around 80 percent in China and several other Asian countries.
As per the pact, the Chinese company will be responsible for exclusive development and commercialization of the Nafithromycin in the select markets. Wockhardt will receive an upfront payment and will be eligible for regulatory-linked milestone payments.
Wockhardt would supply the product to the Chinese company and will receive royalties on net sales and would transfer the manufacturing technology at mutually agreed time, the statement said.
"Bacterial pneumonia and other respiratory tract infections trigger the highest volume of antibiotic prescriptions world over. Prevalence of antimicrobial resistance poses a therapeutic challenge to physicians with extremely limited safer and effective therapeutic options, particularly for most vulnerable group such as pediatric and older age group patients," said Mahesh Patel, chief scientific officer of Wockhardt. Enditem
A single purchase
